We propose a deep subwavelength plasmonic cavity based on a metal-coated coaxial structure with G e 0.9 S n 0.1 as the active medium. A fundamental surface plasmon polariton mode is strongly confined on the sidewall of the metal core, with the quality factor up to 5 × 10 3 at 10 K. By reducing the cavity dimension to a few nanometers, this cavity mode shows a strong plasmon binding with the mode volume down to 8 × 10 − 10 ( λ / n ) 3 , and significant size-dependent damping caused by the non-local optical response. The Purcell factor is achieved as high as 2 × 10 9 at 10 K and 7 × 10 8 at 300 K. This cavity design provides a systematic guideline of scaling down the cavity size and enhancing the Purcell factor. Our theoretical demonstration and understanding of the subwavelength plasmonic cavity represent a significant step toward the large-scale integration of on-chip lasers with a low threshold.

miR-1301 is a newly discovered miRNA, which is abnormally expressed in 14 types of tumors. miR-1301 inhibits 23 target genes, forms a ceRNA network with 2 circRNAs and 8 lncRNAs, and participates in 6 signaling pathways, thereby affecting tumor cell proliferation, invasion, metastasis, apoptosis, angiogenesis, etc. Abnormal expression of miR-1301 is often associated with poor prognosis of cancer patients. In addition, miR-1301 is related to the anti-tumor effect of epirubicin on osteosarcoma and imatinib on chronic myeloid leukemia(CML) and can enhance the cisplatin sensitivity of ovarian cancer. This work systematically summarizes the abnormal expression and prognostic value of miR-1301 in a variety of cancers, depicts the miR-1301-related signaling pathways and ceRNA network, and provides potential clues for future miR-1301 research.

amplifications (CNA), single nucleotide variants (SNV), and insertion-deletions (indel) were identified. Results: ERBB2 alterations were detected in 50 patients (10.8%). ERBB2 SNV, CNA, and indel were found in 27 (5.8%), 25 (5.4%), and 9 (1.9%) patients, respectively. ERBB2 amplification was most frequently identified in gastric (20%; 5/25), colorectal (9.3%; 4/43), lung (4%; 9/226), and breast (3.2%; 1/31) cancer patients. It was often mutually exclusive with other oncogenic drivers in gastric (80%; 4/5) and colorectal (50%; 2/4) but not in other cancers, where concurrent activating BRAF, RAS, and EGFR mutations were observed. Mean ERBB2 CN was also higher in gastric and colorectal cancers compared to others (14.3 vs 3.5, respectively). Interestingly, one gastric cancer patient, whose ERBB2 CNA was identified after progression on 4 prior therapies, demonstrated disease stabilization upon initiation of trastuzumab/FOLFOX. Conclusions: Our data indicate that ERBB2 amplification is a common event in several solid tumor types among East Asian cancer patients. In particular, higher ERBB2 incidence and CN were observed in gastric and colorectal cancer patients in the absence of other oncogenic alterations, underscoring its likely role as the driver in those settings. Finally, we show the potential of comprehensive cfDNA testing in identifying patients who may benefit from HER2-targeted therapies.